A series of pyrazolo[10,50:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones was synthesized and tested in radioligand binding assays to determine their affinities for the human adenosine A1, A2A, A2B and A3 receptors. Results indicated that this scaffold is appropriate for adenosine receptor subtype A1 ligands and that the best arranged groups around this scaffold are 3- and 4-pyridinyl at position 1, benzyl at position 3, hydrogen at position 6 and 3-thienyl or phenyl at position 9. The most interesting compounds showed Ki for A1 in the nanomolar range and an appreciable selectivity for other receptor subtypes.
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands / M. Giovannoni; C. Vergelli; A. Cilibrizzi; L. Crocetti; C. Biancalani; A. Graziano; V. Dal Piaz; M.I. Loza; M.I Cadavid; J. L. Diaz; A. Gavaldà. - In: BIOORGANIC & MEDICINAL CHEMISTRY. - ISSN 0968-0896. - ELETTRONICO. - 18:(2010), pp. 7890-7899.
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands
GIOVANNONI, MARIA PAOLA;VERGELLI, CLAUDIA;CROCETTI, LETIZIA;DAL PIAZ, VITTORIO;
2010
Abstract
A series of pyrazolo[10,50:1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones was synthesized and tested in radioligand binding assays to determine their affinities for the human adenosine A1, A2A, A2B and A3 receptors. Results indicated that this scaffold is appropriate for adenosine receptor subtype A1 ligands and that the best arranged groups around this scaffold are 3- and 4-pyridinyl at position 1, benzyl at position 3, hydrogen at position 6 and 3-thienyl or phenyl at position 9. The most interesting compounds showed Ki for A1 in the nanomolar range and an appreciable selectivity for other receptor subtypes.File | Dimensione | Formato | |
---|---|---|---|
398887 2010.pdf
Accesso chiuso
Tipologia:
Altro
Licenza:
Tutti i diritti riservati
Dimensione
443.8 kB
Formato
Adobe PDF
|
443.8 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.